{"id":251830,"date":"2021-01-11T00:00:00","date_gmt":"2021-01-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcv0044-biopharma-coronary-heart-disease-epidemiology-asia\/"},"modified":"2026-04-22T05:22:35","modified_gmt":"2026-04-22T05:22:35","slug":"epidcv0044-biopharma-coronary-heart-disease-epidemiology-asia-pacific","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcv0044-biopharma-coronary-heart-disease-epidemiology-asia-pacific\/","title":{"rendered":"Coronary Heart Disease &#8211; Epidemiology &#8211; Asia-Pacific"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of coronary heart disease (<abbr title=\"coronary heart disease\">CHD<\/abbr>) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of CHD for each country as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"coronary heart disease\">CHD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of <abbr title=\"coronary heart disease\">CHD<\/abbr>?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"coronary heart disease\">CHD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts four <abbr title=\"coronary heart disease\">CHD<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases: <abbr title=\"coronary heart disease\">CHD<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases: <abbr title=\"coronary heart disease\">CHD<\/abbr> with stable angina.<\/li>\n<li>Diagnosed prevalent cases: <abbr title=\"coronary heart disease\">CHD<\/abbr> with no\u00a0stable angina.<\/li>\n<li>Diagnosed incident cases : <abbr title=\"coronary heart disease\">CHD<\/abbr>.<\/li>\n<\/ul>\n<p>Note: coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251830","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-coronary-heart-disease","biopharma-product-epidemiology","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251830\/revisions"}],"predecessor-version":[{"id":284286,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251830\/revisions\/284286"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}